Clinical trial:
A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
Scientific publications:
Tutykhina I, Esmagambetov I, Bagaev A, et al. Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. Published 2018 Jan 29.
Tutykhina IL, Logunov DY, Shcherbinin DN, et al. Development of adenoviral vector-based mucosal vaccine against influenza. 2011. J Mol Med (Berl).
International patents:
Patent WO2013129961A1 Recombinant trivalent vaccine against human influenza.